Objective: Dopamine (DA) agonists are used to treat the motor symptoms of Parkinson's disease (PD) but often result in behavioral side effects, such as pathological gambling. Given these behaviors are likely associated with DA reward systems, we examined whether PD patients on a DA agonist (PD+DA) differed from PD patients off an agonist (PD-DA) using the Sensitivity to Punishment-Sensitivity to Reward Scale (SPSRQ). Method: A convenience sample of PD patients was categorized as PD+DA (n = 90) or PD-DA (n = 49) based on current use of a DA agonist. Healthy controls (HC; n = 60) were also examined. Groups did not differ in age or education. PD+DA and PD-DA groups did not differ in motor severity, but PD+DA had greater dopamine equivalency levels and longer disease duration. The SPSRQ, along with the Geriatric Depression Scale (GDS) and the State Trait Anxiety Inventory (STAI) were administered. Results: After accounting for...

Article PDF first page preview

Article PDF first page preview
Article PDF first page preview
You do not currently have access to this article.